Highest-materiality recent filing
CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B
Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.
CRISPR Therapeutics completes $600M convertible note offering due 2031
Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.
CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon
Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.
CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M
Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.
CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.
Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).
CRISPR Therapeutics files $600M ATM offering through Jefferies
Filed prospectus supplement to sell up to $600M of common shares at-the-market.
Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.
CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026
CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.
CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM
New director Briggs W. Morrison, M.D. elected; board size maximum increased.
CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data
Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.
CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction
Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.
CRSP COO Julianne Bruno steps down effective April 11, 2025
Julianne Bruno resigns as COO of CRISPR Therapeutics to pursue external opportunities.
CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated
Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.
CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada
Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.
CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs
Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.
CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors
Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).
CRISPR Therapeutics appoints Julianne Bruno as COO effective May 23, 2024
Bruno previously SVP and Head of Programs & Portfolio; led hemoglobinopathy partnership with Vertex.
Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.
On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.
On May 23, 2024, CRISPR Therapeutics AG (the “Company”) announced the promotion of Julianne Bruno, currently the Company’s Senior Vice President and Head of Programs & Portfolio, to be the Company’s Chief Operating Officer effective as of May 23, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings